| 1. Reddy KA, Lohray BB, Bhushan V, Reddy AS, Kishore PH, Rao VV, Saibaba V, Bajji AC, Rajesh BM, Reddy KV, Chakrabarti R, Rajagopalan R.. (1998) Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif., 8 (9): [PMID:9871696] [10.1016/s0960-894x(98)00159-0] |
| 2. Malamas MS, Sredy J, Gunawan I, Mihan B, Sawicki DR, Seestaller L, Sullivan D, Flam BR.. (2000) New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties., 43 (5): [PMID:10715163] [10.1021/jm990476x] |
| 3. Cantello BC, Cawthorne MA, Haigh D, Hindley RM, Smith SA, Thurlby PL. (1994) The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent, 4 (10): [10.1016/S0960-894X(01)80325-5] |
| 4. Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Vikramadithyan RK, Rajagopalan R, Mamidi RN, Jajoo HK, Subramaniam S.. (1998) Novel euglycemic and hypolipidemic agents. 1., 41 (10): [PMID:9572887] [10.1021/jm970444e] |
| 5. Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, Uchida I.. (1998) Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents., 41 (11): [PMID:9599241] [10.1021/jm970771m] |
| 6. Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, Uchida I.. (1998) Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents., 41 (11): [PMID:9599241] [10.1021/jm970771m] |
| 7. Reddy KA, Lohray BB, Bhushan V, Bajji AC, Reddy KV, Reddy PR, Krishna TH, Rao IN, Jajoo HK, Rao NV, Chakrabarti R, Dileepkumar T, Rajagopalan R.. (1999) Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones., 42 (11): [PMID:10354401] [10.1021/jm980549x] |
| 8. Reddy KA, Lohray BB, Bhushan V, Bajji AC, Reddy KV, Reddy PR, Krishna TH, Rao IN, Jajoo HK, Rao NV, Chakrabarti R, Dileepkumar T, Rajagopalan R.. (1999) Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones., 42 (11): [PMID:10354401] [10.1021/jm980549x] |
| 9. Brooks DA, Etgen GJ, Rito CJ, Shuker AJ, Dominianni SJ, Warshawsky AM, Ardecky R, Paterniti JR, Tyhonas J, Karanewsky DS, Kauffman RF, Broderick CL, Oldham BA, Montrose-Rafizadeh C, Winneroski LL, Faul MM, McCarthy JR.. (2001) Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists., 44 (13): [PMID:11405642] [10.1021/jm0155188] |
| 10. Buckle D, Cantello B, Cawthorne M, Coyle P, Dean D, Faller A, Haigh D, Hindley R, Jefcott L, Lister C, Pinto I, Rami H, Smith D, Smith S. (1996) Non thiazolidinedione antihyperglycaemic agents. 1: -Heteroatom substituted -phenylpropanoic acids, 6 (17): [10.1016/0960-894X(96)00383-6] |
| 11. Buckle D, Cantello B, Cawthorne M, Coyle P, Dean D, Faller A, Haigh D, Hindley R, Jefcott L, Lister C, Pinto I, Rami H, Smith D, Smith S. (1996) Non thiazolidinedione antihyperglycaemic agents. 2: -Carbon substituted -phenylpropanoic acids1, 6 (17): [10.1016/0960-894X(96)00382-4] |
| 12. Fan YH, Chen H, Natarajan A, Guo Y, Harbinski F, Iyasere J, Christ W, Aktas H, Halperin JA.. (2004) Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium., 14 (10): [PMID:15109648] [10.1016/j.bmcl.2004.02.087] |
| 13. Prabhakar C, Madhusudhan G, Sahadev K, Reddy CM, Sarma MR, Reddy GO, Chakrabarti R, Rao CS, Kumar TD, Rajagopalan R.. (1998) Synthesis and biological activity of novel thiazolidinediones., 8 (19): [PMID:9873611] [10.1016/s0960-894x(98)00485-5] |
| 14. Wrobel J, Sredy J, Moxham C, Dietrich A, Li Z, Sawicki DR, Seestaller L, Wu L, Katz A, Sullivan D, Tio C, Zhang ZY.. (1999) PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes., 42 (17): [PMID:10464006] [10.1021/jm990260v] |
| 15. Reddy KA, Lohray BB, Bhushan V, Reddy AS, Rao Mamidi NV, Reddy PP, Saibaba V, Reddy NJ, Suryaprakash A, Misra P, Vikramadithyan RK, Rajagopalan R.. (1999) Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives., 42 (17): [PMID:10464013] [10.1021/jm9805541] |
| 16. Henke BR, Adkison KK, Blanchard SG, Leesnitzer LM, Mook RA, Plunket KD, Ray JA, Roberson C, Unwalla R, Willson TM.. (1999) Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists., 9 (23): [PMID:10612594] [10.1016/s0960-894x(99)00603-4] |
| 17. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL.. (1994) [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents., 37 (23): [PMID:7966158] [10.1021/jm00049a017] |
| 18. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H.. (1989) Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation., 32 (2): [PMID:2913302] [10.1021/jm00122a022] |
| 19. Aicher TD, Balkan B, Bell PA, Brand LJ, Cheon SH, Deems RO, Fell JB, Fillers WS, Fraser JD, Gao J, Knorr DC, Kahle GG, Leone CL, Nadelson J, Simpson R, Smith HC.. (1998) Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents., 41 (23): [PMID:9804695] [10.1021/jm9803121] |
| 20. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM.. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents., 41 (25): [PMID:9836620] [10.1021/jm9804127] |
| 21. Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, Collins JL, Dezube M, Henke BR, Hull-Ryde EA, Lake DH, Lenhard JM, Oliver W, Oplinger J, Pentti M, Parks DJ, Plunket KD, Tong WQ.. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent., 41 (25): [PMID:9836622] [10.1021/jm980414r] |
| 22. Nomura M, Kinoshita S, Satoh H, Maeda T, Murakami K, Tsunoda M, Miyachi H, Awano K.. (1999) (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents., 9 (4): [PMID:10098657] [10.1016/s0960-894x(99)00039-6] |
| 23. Willson TM, Brown PJ, Sternbach DD, Henke BR.. (2000) The PPARs: from orphan receptors to drug discovery., 43 (4): [PMID:10691680] [10.1021/jm990554g] |
| 24. Lohray BB, Bhushan V, Rao P, Madhavan G, Murali N, Rao K, Madhavan G, Murali N, Rao K, Anantha Reddy K, Rajesh B, Ganpathy Reddy P, Chakrabarti R, Rajagopalan R. (1997) Novel indole containing thiazolidinedione derivatives as potent euglycemic and hypolipidaemic agents, 7 (7): [10.1016/S0960-894X(97)00118-2] |
| 25. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Wöldike HF, Fleckner J, Andersen AS, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM.. (2002) Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity., 45 (4): [PMID:11831892] [10.1021/jm010964g] |
| 26. Chen H, Fan YH, Natarajan A, Guo Y, Iyasere J, Harbinski F, Luus L, Christ W, Aktas H, Halperin JA.. (2004) Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation., 14 (21): [PMID:15454234] [10.1016/j.bmcl.2004.08.017] |
| 27. Wang YH, Li Y, Li YH, Yang SL, Yang L.. (2005) Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism., 15 (18): [PMID:15990295] [10.1016/j.bmcl.2005.06.015] |
| 28. Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.. (2006) Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents., 16 (24): [PMID:17005393] [10.1016/j.bmcl.2006.09.028] |
| 29. Bergström CA, Wassvik CM, Johansson K, Hubatsch I.. (2007) Poorly soluble marketed drugs display solvation limited solubility., 50 (23): [PMID:17929794] [10.1021/jm0706416] |
| 30. Zhang H, Matsuda H, Kumahara A, Ito Y, Nakamura S, Yoshikawa M.. (2007) New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium)., 17 (17): [PMID:17609121] [10.1016/j.bmcl.2007.06.027] |
| 31. Yang J, Wei S, Wang DS, Wang YC, Kulp SK, Chen CS.. (2008) Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents., 51 (7): [PMID:18335975] [10.1021/jm701212m] |
| 32. Romeiro NC, Sant'Anna CM, Lima LM, Fraga CA, Barreiro EJ.. (2008) NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma)., 43 (9): [PMID:18222570] [10.1016/j.ejmech.2007.11.031] |
| 33. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.. (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1., 51 (19): [PMID:18788725] [10.1021/jm8003152] |
| 34. Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z.. (2009) First-principle, structure-based prediction of hepatic metabolic clearance values in human., 44 (4): [PMID:18768239] [10.1016/j.ejmech.2008.07.027] |
| 35. Zhang H, Matsuda H, Nakamura S, Yoshikawa M.. (2008) Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells., 18 (11): [PMID:18477507] [10.1016/j.bmcl.2008.04.052] |
| 36. Kunimasa K, Kuranuki S, Matsuura N, Iwasaki N, Ikeda M, Ito A, Sashida Y, Mimaki Y, Yano M, Sato M, Igarashi Y, Oikawa T.. (2009) Identification of nobiletin, a polymethoxyflavonoid, as an enhancer of adiponectin secretion., 19 (7): [PMID:19268587] [10.1016/j.bmcl.2009.02.002] |
| 37. Bhattarai BR, Kafle B, Hwang JS, Khadka D, Lee SM, Kang JS, Ham SW, Han IO, Park H, Cho H.. (2009) Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects., 19 (21): [PMID:19783142] [10.1016/j.bmcl.2009.09.020] |
| 38. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.. (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells., 2 (6): [PMID:16680159] [10.1038/nchembio790] |
| 39. Geldenhuys WJ, Darvesh AS, Funk MO, Van der Schyf CJ, Carroll RT.. (2010) Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening., 20 (17): [PMID:20650633] [10.1016/j.bmcl.2010.06.128] |
| 40. Madonna S, Maher P, Kraus JL.. (2010) N,N-Bis-(8-hydroxyquinoline-5-yl methyl)-benzyl substituted amines (HQNBA): peroxisome proliferator-activated receptor (PPAR-γ) agonists with neuroprotective properties., 20 (23): [PMID:20971007] [10.1016/j.bmcl.2010.09.134] |
| 41. PubChem BioAssay data set, |
| 42. PubChem BioAssay data set, |
| 43. PubChem BioAssay data set, |
| 44. PubChem BioAssay data set, |
| 45. Jolivette LJ, Ward KW.. (2005) Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure., 94 (7): [PMID:15920768] [10.1002/jps.20373] |
| 46. Ward KW, Nagilla R, Jolivette LJ.. (2005) Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human., 35 (2): [PMID:16019946] [10.1080/00498250400028197] |
| 47. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 48. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 49. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 50. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.. (2008) Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models., 18 (2): [PMID:20020916] [10.1080/15376510701857262] |
| 51. Unpublished dataset, |
| 52. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 53. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 54. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 55. Matsuda H, Kogami Y, Nakamura S, Sugiyama T, Ueno T, Yoshikawa M.. (2011) Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells., 19 (9): [PMID:21493073] [10.1016/j.bmc.2011.03.040] |
| 56. Kiang TK, Ensom MH, Chang TK.. (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions., 106 (1): [PMID:15781124] [10.1016/j.pharmthera.2004.10.013] |
| 57. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 58. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007] |
| 59. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 60. Kim Y, George D, Prior AM, Prasain K, Hao S, Le DD, Hua DH, Chang KO.. (2012) Novel triacsin C analogs as potential antivirals against rotavirus infections., 50 [PMID:22365411] [10.1016/j.ejmech.2012.02.010] |
| 61. Hong SS, Lee JH, Jeong W, Kim N, Jin HZ, Hwang BY, Lee HJ, Lee SJ, Jang DS, Lee D.. (2012) Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes., 22 (6): [PMID:22342624] [10.1016/j.bmcl.2012.01.070] |
| 62. Salamone S, Colin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Flament S, Martin H, Richert L, Chapleur Y, Boisbrun M.. (2012) Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study., 51 [PMID:22409968] [10.1016/j.ejmech.2012.02.044] |
| 63. Quang TH, Ngan NT, Minh CV, Kiem PV, Tai BH, Thao NP, Song SB, Kim YH.. (2012) Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii., 22 (7): [PMID:22381047] [10.1016/j.bmcl.2012.01.136] |
| 64. Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE.. (2012) Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs., 3 (1): [PMID:22282722] [10.1021/ml200196p] |
| 65. Kim T, Lee W, Jeong KH, Song JH, Park SH, Choi P, Kim SN, Lee S, Ham J.. (2012) Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives., 22 (12): [PMID:22579420] [10.1016/j.bmcl.2012.04.062] |
| 66. Barros FW, Silva TG, da Rocha Pitta MG, Bezerra DP, Costa-Lotufo LV, de Moraes MO, Pessoa C, de Moura MA, de Abreu FC, de Lima Mdo C, Galdino SL, Pitta Ida R, Goulart MO.. (2012) Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives., 20 (11): [PMID:22546208] [10.1016/j.bmc.2012.04.007] |
| 67. Hiep NT, Choi YH, Kim N, Hong SS, Hong SB, Hwang BY, Lee HJ, Lee SJ, Jang DS, Lee D.. (2012) Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma., 75 (4): [PMID:22424300] [10.1021/np200955z] |
| 68. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.. (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., 25 (10): [PMID:22931300] [10.1021/tx300075j] |
| 69. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I.. (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity., 32 (1): [PMID:14977862] [10.1124/dmd.32.3.291] |
| 70. Wang EJ, Casciano CN, Clement RP, Johnson WW.. (2003) Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites., 20 (1): [PMID:12739759] [10.1023/a:1023278211849] |
| 71. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R.. (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate., 167 (1): [PMID:11557132] [10.1016/s0300-483x(01)00460-7] |
| 72. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 73. PubChem BioAssay data set, |
| 74. PubChem BioAssay data set, |
| 75. Baumgartner L, Sosa S, Atanasov AG, Bodensieck A, Fakhrudin N, Bauer J, Favero GD, Ponti C, Heiss EH, Schwaiger S, Ladurner A, Widowitz U, Loggia RD, Rollinger JM, Werz O, Bauer R, Dirsch VM, Tubaro A, Stuppner H.. (2011) Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro., 74 (8): [PMID:21800856] [10.1021/np200343t] |
| 76. Quang TH, Ngan NT, Minh CV, Kiem PV, Yen PH, Tai BH, Nhiem NX, Thao NP, Anh Hle T, Luyen BT, Yang SY, Choi CW, Kim YH.. (2012) Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-κB activation and PPAR transcriptional activity., 22 (21): [PMID:23031596] [10.1016/j.bmcl.2012.08.099] |
| 77. Lin HR.. (2012) Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists., 22 (8): [PMID:22424975] [10.1016/j.bmcl.2012.02.043] |
| 78. Hoang MH, Jia Y, Jun HJ, Lee JH, Lee DH, Hwang BY, Kim WJ, Lee HJ, Lee SJ.. (2012) Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells., 22 (12): [PMID:22579484] [10.1016/j.bmcl.2012.04.071] |
| 79. Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.. (2012) Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2., 22 (24): [PMID:23122865] [10.1016/j.bmcl.2012.10.010] |
| 80. Porcelli L, Gilardi F, Laghezza A, Piemontese L, Mitro N, Azzariti A, Altieri F, Cervoni L, Fracchiolla G, Giudici M, Guerrini U, Lavecchia A, Montanari R, Di Giovanni C, Paradiso A, Pochetti G, Simone GM, Tortorella P, Crestani M, Loiodice F.. (2012) Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity., 55 (1): [PMID:22081932] [10.1021/jm201306q] |
| 81. Lee M, Song JY, Chin YW, Sung SH.. (2013) Anti-adipogenic diarylheptanoids from Alnus hirsuta f. sibirica on 3T3-L1 cells., 23 (7): [PMID:23465614] [10.1016/j.bmcl.2013.01.127] |
| 82. Mourad AA, Nakamura S, Ueno T, Minami T, Yagi T, Yasue H, Komatsu R, Yoshikawa M, Taye AM, El-Moselhy MA, Khalifa MM, Matsuda H.. (2013) Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells., 23 (17): [PMID:23910984] [10.1016/j.bmcl.2013.06.101] |
| 83. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 84. PubChem BioAssay data set, |
| 85. PubChem BioAssay data set, |
| 86. PubChem BioAssay data set, |
| 87. Bordessa A, Colin-Cassin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Husson G, Vo M, Flament S, Martin H, Chapleur Y, Boisbrun M.. (2014) Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds., 83 [PMID:24953030] [10.1016/j.ejmech.2014.06.015] |
| 88. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 89. Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning, [10.6019/CHEMBL3392926] |
| 90. Patel H, Sonawane Y, Jagtap R, Dhangar K, Thapliyal N, Surana S, Noolvi M, Shaikh MS, Rane RA, Karpoormath R.. (2015) Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS., 25 (9): [PMID:25851939] [10.1016/j.bmcl.2015.03.020] |
| 91. Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.. (2012) Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment., 32 [PMID:22761000] [10.1002/jat.2784] |
| 92. Dawson S, Stahl S, Paul N, Barber J, Kenna JG.. (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans., 40 (1): [PMID:21965623] [10.1124/dmd.111.040758] |
| 93. Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin CP, Xia M.. (2011) Identification of clinically used drugs that activate pregnane X receptors., 39 (1): [PMID:20966043] [10.1124/dmd.110.035105] |
| 94. Chadha N, Bahia MS, Kaur M, Silakari O.. (2015) Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions., 23 (13): [PMID:25890697] [10.1016/j.bmc.2015.03.071] |
| 95. Fauber BP, Gobbi A, Robarge K, Zhou A, Barnard A, Cao J, Deng Y, Eidenschenk C, Everett C, Ganguli A, Hawkins J, Johnson AR, La H, Norman M, Salmon G, Summerhill S, Ouyang W, Tang W, Wong H.. (2015) Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists., 25 (15): [PMID:26048793] [10.1016/j.bmcl.2015.05.055] |
| 96. IC50 data for the L-type calcium channel extracted from a set of literature articles, |
| 97. Unpublished dataset, |
| 98. WHO Anatomical Therapeutic Chemical Classification, |
| 99. British National Formulary (72nd edition), |
| 100. Morita M, Naito Y, Yoshikawa T, Niki E.. (2016) Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs., 26 (22): [PMID:27777006] [10.1016/j.bmcl.2016.10.033] |
| 101. DrugMatrix, [10.6019/CHEMBL3885881] |
| 102. Fueyo González FJ, Ebiloma GU, Izquierdo García C, Bruggeman V, Sánchez Villamañán JM, Donachie A, Balogun EO, Inaoka DK, Shiba T, Harada S, Kita K, de Koning HP, Dardonville C.. (2017) Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion., 60 (4): [PMID:28112515] [10.1021/acs.jmedchem.6b01740] |
| 103. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development., 118 (2): [PMID:20829430] [10.1093/toxsci/kfq269] |
| 104. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.. (2014) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump., 60 (3): [PMID:24799086] [10.1002/hep.27206] |
| 105. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
| 106. Yu J, Ahn S, Kim HJ, Lee M, Ahn S, Kim J, Jin SH, Lee E, Kim G, Cheong JH, Jacobson KA, Jeong LS, Noh M.. (2017) Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential., 60 (17): [PMID:28799755] [10.1021/acs.jmedchem.7b00805] |
| 107. Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Le VP, Levine BH, Ng SC, Ni ZJ, Nuss JM, Pfister KB, Ramurthy S, Renhowe PA, Ring DB, Shu W, Subramanian S, Zhou XA, Shafer CM, Harrison SD, Johnson KW, Bussiere DE.. (2017) Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3., 60 (20): [PMID:29016121] [10.1021/acs.jmedchem.7b00922] |
| 108. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 109. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 110. Ahn S, Lee M, An S, Hyun S, Hwang J, Lee J, Noh M.. (2018) 2-Formyl-komarovicine promotes adiponectin production in human mesenchymal stem cells through PPARγ partial agonism., 26 (5): [PMID:29398443] [10.1016/j.bmc.2018.01.019] |
| 111. Tanis SP, Colca JR, Parker TT, Artman GD, Larsen SD, McDonald WG, Gadwood RC, Kletzien RF, Zeller JB, Lee PH, Adams WJ.. (2018) PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development., 26 (22): [PMID:30429097] [10.1016/j.bmc.2018.10.033] |
| 112. Vesci L, Milazzo FM, Stasi MA, Pace S, Manera F, Tallarico C, Cini E, Petricci E, Manetti F, De Santis R, Giannini G.. (2018) Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo., 157 [PMID:30099257] [10.1016/j.ejmech.2018.07.053] |
| 113. Unpublished dataset, |
| 114. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 115. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek. (2020) Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection, [10.21203/rs.3.rs-23951/v1] |
| 116. Jiang Z, Liu X, Yuan Z, He H, Wang J, Zhang X, Gong Z, Hou L, Shen L, Guo F, Zhang J, Wang J, Xu D, Liu Z, Li H, Chen X, Long C, Li J, Chen S.. (2019) Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis., 10 (7): [PMID:31312410] [10.1021/acsmedchemlett.9b00189] |
| 117. Dupommier D, Muller C, Comoy C, Mazerbourg S, Bordessa A, Piquard E, Pawlak M, Piquard F, Martin H, De Fays E, Grandemange S, Flament S, Boisbrun M.. (2020) New desulfured troglitazone derivatives: Improved synthesis and biological evaluation., 187 [PMID:31838327] [10.1016/j.ejmech.2019.111939] |
| 118. Rana P, Will Y, Nadanaciva S, Jones LH.. (2016) Development of a cell viability assay to assess drug metabolite structure-toxicity relationships., 26 (16): [PMID:27397500] [10.1016/j.bmcl.2016.06.088] |
| 119. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 120. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 121. An S, Yu J, Choi H, Ko H, Ahn S, Shin JC, Pyo JJ, Jeong LS, Noh M.. (2020) Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ., 28 (1): [PMID:31806266] [10.1016/j.bmc.2019.115226] |
| 122. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 123. Norman BH. (2020) Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies., 63 (20.0): [PMID:32511920] [10.1021/acs.jmedchem.0c00524] |
| 124. Kim SO,Han Y,Ahn S,An S,Shin JC,Choi H,Kim HJ,Park NH,Kim YJ,Jin SH,Rho HS,Noh M. (2018) Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists., 26 (21): [PMID:30352713] [10.1016/j.bmc.2018.10.010] |
| 125. An S,Kim G,Kim HJ,Ahn S,Kim HY,Ko H,Hyun YE,Nguyen M,Jeong J,Liu Z,Han J,Choi H,Yu J,Kim JW,Lee HW,Jacobson KA,Cho WJ,Kim YM,Kang KW,Noh M,Jeong LS. (2020) Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators., 63 (24): [PMID:33325691] [10.1021/acs.jmedchem.0c01874] |
| 126. Tabatabaei Dakhili SA,Pérez DJ,Gopal K,Haque M,Ussher JR,Kashfi K,Velázquez-Martínez CA. (2021) SP1-independent inhibition of FOXM1 by modified thiazolidinediones., 209 [PMID:33069434] [10.1016/j.ejmech.2020.112902] |
| 127. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 128. Ko H, Jang H, An S, Park IG, Ahn S, Gong J, Hwang SY, Oh S, Kwak SY, Choi WJ, Kim H, Noh M.. (2022) Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist., 54 [PMID:34922307] [10.1016/j.bmc.2021.116564] |
| 129. Shim S, Krishnaiah M, Sankham MR, Kim I, Lee Y, Shin I, Oh AR, Lee HJ, Vu TNL, Park J, Choi S, Park S, Kwon Y, Fang S, Kim DK.. (2022) Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis., 65 (14.0): [PMID:35797110] [10.1021/acs.jmedchem.2c00641] |
| 130. Chen S, Zhang L, Chen Y, Fu L.. (2022) Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential., 65 (19.0): [PMID:36111355] [10.1021/acs.jmedchem.2c01097] |
| 131. Jadoon R, Aamir Javed M, Saeed Jan M, Ikram M, Mahnashi MH, Sadiq A, Shahid M, Rashid U.. (2022) Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors., 76 [PMID:36162779] [10.1016/j.bmcl.2022.128994] |
| 132. Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED.. (2021) Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches., 64 (10.0): [PMID:34003642] [10.1021/acs.jmedchem.0c02245] |
| 133. Yasmin S, Jayaprakash V.. (2017) Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present., 126 [PMID:27988463] [10.1016/j.ejmech.2016.12.020] |
| 134. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
